A phase III trial (NCT02667587) in glioblastoma patients that present with a methylation of the O6-methylguanine-DNA methyl transferase (MGMT) gene promotor received a combination of nivolumab, TMZ, and radiotherapy. Here, MGMT is linked to glioblastoma.